Most Clicked StoriesMore >


Why Ebola could lead to the next billion-dollar drug

BIO SmartBrief | Oct 30, 2014

Some experts believe that Ebola will give rise to the next $1 billion drug as several small biotech firms and major drugmakers race to develop treatments and vaccines to combat the deadly virus. A Credit Suisse report predicted that contracts worth more than $1 billion can be expected to be awarded by the U.S. government alone to finance huge quantities of Ebola treatment. CNNMoney (10/28)


FDA approves diabetes combo drug from AstraZeneca

BIO SmartBrief | Oct 30, 2014

Bristol gets option to buy cancer-drug developer in deal worth up to $475M

BIO SmartBrief | Oct 29, 2014

CSL pays $275M to purchase Novartis' flu vaccine business

BIO SmartBrief | Oct 28, 2014

BARDA needs more funding to fight Ebola, other threats, lawmaker says

BIO SmartBrief | Oct 27, 2014

Pharma hopes governments, aid groups will pay for Ebola R&D

BIO SmartBrief | Oct 28, 2014

Production obstacles await any successful Ebola vaccine

BIO SmartBrief | Oct 29, 2014

Merck's Keytruda wins FDA breakthrough status for lung cancer

BIO SmartBrief | Oct 28, 2014

Baxter's hemophilia A drug Obizur gets FDA approval

BIO SmartBrief | Oct 27, 2014

Scientists use synthetic biology to develop litmus paper for Ebola

BIO SmartBrief | Oct 30, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the BIO CEO & Investor Conference!

BIO SmartBrief | Oct 31, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Oct 30, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Oct 29, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Oct 28, 2014

Secure document sharing services optimized for life science organizations

BIO SmartBrief | Oct 27, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more